^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DUET-201

    i
    Other names: DUET-201, CpG-STAT3siRNA, CpG-STAT3 siRNA CAS3/SS3, CAS3/SS3, CpG-STAT3 siRNA, CpG ODN/STAT3 siRNA CAS3/SS3, CpG Oligodeoxynucleotide/STAT3 siRNA CAS3/SS3, CpG/Anti-STAT3 siRNA CAS3/SS3, CpG/STAT3 siRNA CAS3/SS3, DUET-01
    Associations

    News

    Trials
    Company:
    Scopus
    Drug class:
    STAT3 inhibitor, TLR9 agonist, Gene silencing
    Related drugs:
    Associations

    News

    Trials
    25d
    Local CpG-Stat3 siRNA treatment improves antitumor effects of immune checkpoint inhibitors. (PubMed, Mol Ther Nucleic Acids)
    Furthermore, locally delivered CpG-Stat3 siRNA enhanced CD8+ T cell tumor infiltration and antitumor activity in a xenograft tumor model. Overall, our studies in both B cell lymphoma and melanoma mouse models demonstrate the potential of combinatory immunotherapy with CpG-Stat3 siRNA and checkpoint inhibitors as a therapeutic strategy for B cell lymphoma and melanoma.
    Journal • Checkpoint inhibition
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • TLR9 (Toll Like Receptor 9)
    |
    DUET-201
    1year
    CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL (clinicaltrials.gov)
    P1, N=0, Withdrawn, City of Hope Medical Center | N=18 --> 0 | Trial completion date: Dec 2024 --> Jan 2024 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2024 --> Jan 2024
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Combination therapy
    |
    DUET-201
    over1year
    Lipid Nanoparticle Formulations for the Systemic Delivery of CpG-STAT3 siRNA to Myeloid Immune Cell for Cancer Immunotherapy (ASGCT 2023)
    While studies are ongoing, our results so far suggest potential species-specific differences between LNP targeting properties and underscore the need for testing in the context of human immune system in vitro or in humanized mouse models. We believe that the new LNP2PG formulation will provide vehicle for targeting human hematologic malignancies and solid tumors which rely on the tolerogenic myeloid cells for immune evasion.
    Immune cell
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • TLR9 (Toll Like Receptor 9) • IFNA1 (Interferon Alpha 1)
    |
    DUET-201
    almost2years
    CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL (clinicaltrials.gov)
    P1, N=18, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2024 --> Dec 2024 | Trial primary completion date: Jan 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    STAT3 expression
    |
    DUET-201
    over2years
    CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL (clinicaltrials.gov)
    P1, N=18, Recruiting, City of Hope Medical Center | Initiation date: May 2022 --> Aug 2022
    Trial initiation date • Combination therapy
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    STAT3 expression
    |
    DUET-201
    over2years
    Lipid Nanoparticle Formulation Enhances Gene Silencing, Immunostimulatory Properties and In Vivo Efficacy of CpG-STAT3siRNA Against Human B Cell Lymphoma (ASGCT 2022)
    These studies indicated ~10-fold increase in the potency of our oligonucleotide in local administration resulting in lymphoma growth arrest. While further studies in syngeneic lymphoma models are ongoing, our data suggest that the new LNP-02 formulation of CpG-STAT3siRNA can provide an attractive new therapeutic option for the immunotherapy of B cell lymphoma and potentially certain other malignancies.
    Preclinical • IO biomarker
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • IFNA1 (Interferon Alpha 1)
    |
    DUET-201
    almost3years
    CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL (clinicaltrials.gov)
    P1, N=18, Recruiting, City of Hope Medical Center | Trial completion date: Jul 2023 --> Jan 2024 | Trial primary completion date: Jul 2023 --> Jan 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    STAT3 expression
    |
    DUET-201
    over3years
    CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL (clinicaltrials.gov)
    P1, N=18, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    STAT3 expression
    |
    DUET-201
    over3years
    CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, City of Hope Medical Center
    Clinical • New P1 trial • Combination therapy
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    STAT3 expression
    |
    DUET-201